#NeoMastodon #Pediatrics #MedMastodon #Nicuverse
While having some train time, I had some time to summarize some thoughts about the difficult discussion and debate that is emerging in Sweden, about what is in the best interest of infants born at 22 and 23 weeks. It is a longer blog post on the @99nicu web site, but wanted to share the link to it here in the #nicuverse as well. I looking fw to hear your thoughts.
https://99nicu.org/blogs/entry/457-quality-of-life-in-adults-born-extremely-preterm-and-large-gap-between-what-we-know-and-what-we-need-to-know/
#NeoMastodon

Sweden is a good country to be born extremely preterm. Neonatal intensive care is centralized and pretty much equally organized, and outcomes are regarded as good and similar throughout the country. Like in most other European countries, the welfare system enables equal access for all, practicall...
RE: https://nicuverse.org/@JAPANicu/116587394271004959
Dear all in the #NICUverse and on #NeoMastodon, please take the survey below!

Neonatal sepsis remains one of the leading causes of death and harm in newborns worldwide, and it disproportionately affects babies in low- and middle-income settings.This week at the PAS 2026 conference, a new global initiative took its first formal step: the Newborn Sepsis Society held its foun...
Help Select the 2025 EBNEO Impact Article of the Year!
The race has reached its final showdown. After a highly competitive first round involving eight outstanding articles, two landmark RCTs have emerged as the clear frontrunners: Faix et al. (Preterm Hypothermia) and Laughon et al. (PDA Management). Because the margin was incredibly narrow, we are opening one final head-to-head vote to determine the definitive winner for 2025.
#nicuverse and #NeoMastodon - vote here! https://ebneo.org/impact
Which Publication Will Be Crowned the 2025 EBNEO Impact Article of the Year? After a highly competitive first round involving eight outstanding articles, two finalists have risen to the top. While the margin was incredibly narrow, Faix et al. and Laughon et al. are our clear frontrunners. We are now opening one final head-to-head vote โฆ Continue reading "Article of the Year"
Listen to this great @nicupodcast session with Prof Brett Manley explaining adaptive platform trials, the new black in trial design.
@Brett - good work, with the Platipus platform you are on to something that will have true impact for the #nicuverse! Looking fw what to come!

Hello friends ๐In this interview episode, Ben and Daphna sit down with Professor Brett Manley to discuss a paradigm shift in neonatal research: adaptive platform trials. Frustrated by the inefficiencies and underpowered results of traditional RCTs, Dr. Manley outlines the ambitious Platypus Adaptive Platform Trial launching in Australia and New Zealand. They dive into how shared primary outcomes, novel consent models, and massive cross-center collaboration can answer pressing clinical questions